Sonoma Pharmaceuticals (SNOA) Income from Non-Controlling Interests (2020 - 2021)
Sonoma Pharmaceuticals (SNOA) posted quarterly Income from Non-Controlling Interests of $1.0 million for Q4 2021, up 372.7% year-over-year from $213453.4 in Q4 2020, and up 202.1% quarter-over-quarter from $334000.0 in Q3 2021.
Sonoma Pharmaceuticals (SNOA) Income from Non-Controlling Interests (2020 - 2021) Analysis & Trends
Sonoma Pharmaceuticals' Income from Non-Controlling Interests history runs 2 years deep, the most recent figure standing at $1.0 million for Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.05 Bn | 43.08 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.39 Bn | 39.74 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.86 Bn | 30.18 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.78 Bn | 22.99 Bn | 5.10 Bn | 376,434.15 |
| 5 | United Therapeutics | 22.25 Bn | 19.59 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.74 Bn | 17.85 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.58 Bn | 15.19 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.92 Bn | 11.39 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 9.99 Bn | - | - |
| 10 | Sonoma Pharmaceuticals | 5.08 Mn | -261,279.80 | 2.58 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 1.01 Mn |
| Sep 30, 2021 | 334,000.00 |
| Jun 30, 2021 | 791,000.00 |
| Dec 31, 2020 | -370,000.00 |
| Sep 30, 2020 | -308,000.00 |
| Jun 30, 2020 | -407,000.00 |